NASDAQ$TNGX

Tango Therapeutics Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Headline financials

Total Revenue

$6.41M

Previous: $5.72M+12.2%
EPS (adj)

-$0.33

Previous: -$0.25-32.0%
Capital Expenditures

$1.04M

Previous: $696K+49.6%
Free Cash Flow

-$29.3M

Previous: -$17.6M-66.5%
Net Income

-$29.1M

Previous: -$22M-31.8%
Operating Income

-$30.6M

Previous: -$22M-39.0%
Gross Profit

$6.41M

Previous: $5.72M+12.2%
Cash & Equivalents

$60M

Previous: $143M-58.0%
Total Assets

$436M

Previous: $500M-12.7%
Stock-Based Comp

$3.79M

Previous: $2.26M+67.7%

Revenue & EPS history

Tango Therapeutics · Revenue · Quarterly

$6.41M

Q4 2022+12.2%vs Q4 2021
Beat estimate in 6 of 13 quarters(46%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+0.6%

Avg return

Earnings day

+6.7%

Avg return

5 days after

+25.5%

Avg return

30 days after

58%

11 / 19 earnings

Positive

+36.4%

Q4 2025

Best reaction

-45.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+8.6%-12.1%
Q4 2025+36.4%+33.6%+75.1%
Q3 2025+0.2%-1.7%+23.6%
Q1 2025+17.1%+31.6%+315.8%
Q4 2024-6.5%-21.0%-36.9%
Q3 2024-45.4%-34.7%-34.7%
Q2 2024-1.8%-5.7%+20.9%
Q1 2024-0.8%-6.9%-12.1%
Q4 2023-9.7%-14.4%-17.4%
Q3 2023+3.8%-12.1%+6.6%
Q2 2023+1.2%+120.9%+113.5%
Q1 2023+6.4%+4.4%-0.3%
Q4 2022-9.4%-5.3%-21.6%
Q3 2022-5.3%+6.7%-1.3%
Q2 2022+22.4%+32.8%-8.1%
Q1 2022-7.6%+1.2%-3.8%
Q4 2021+0.3%+6.8%+1.3%
Q3 2021+0.4%+5.2%-10.7%
Q2 2021+1.1%-2.2%+49.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro